(Q43084552)

13 November 2017

title

In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia (English)

1 reference

13 November 2017

0 references

2

1 reference

13 November 2017

5

1 reference

13 November 2017

Laura C Amann

1

1 reference

13 November 2017

Robert Lin

series ordinal

3

1 reference

13 November 2017

Yuling Liang

series ordinal

4

1 reference

13 November 2017

publication date

27 April 2010

1 reference

13 November 2017

published in

Pharmaceutical Research

1 reference

13 November 2017

volume

27

1 reference

13 November 2017

issue

8

1 reference

13 November 2017

page(s)

1730-1737

1 reference

Cost of relapse in schizophrenia

13 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-010-0152-4

Biodegradable microspheres in drug delivery

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-010-0152-4

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-010-0152-4

Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.

21 January 2018

1 reference

12 December 2020

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1 reference

12 December 2020

Utilization of long-acting antipsychotic medication in patient care

1 reference

12 December 2020

Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia

1 reference

12 December 2020

Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking

1 reference

12 December 2020

Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia

1 reference

12 December 2020

The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.

1 reference

12 December 2020

Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits.

1 reference

12 December 2020

Risperidone-induced hepatotoxicity

1 reference

12 December 2020

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

12 December 2020

Hospitalization and total medical costs for privately insured persons with schizophrenia

1 reference

12 December 2020

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

1 reference

12 December 2020

Relapse and rehospitalization: comparing oral and depot antipsychotics.

1 reference

12 December 2020

Changing from oral to depot fluphenazine

1 reference

12 December 2020

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

1 reference

12 December 2020

The Economic Burden of Schizophrenia in the United States in 2002

1 reference

12 December 2020

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

1 reference

12 December 2020

The mean dissolution time depends on the dose/solubility ratio

1 reference

12 December 2020

In vivo and in vitro degradation of glycine/DL-lactic acid copolymers

1 reference

12 December 2020

The economic impact of schizophrenia

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

In vitro and in vivo demonstration of risperidone implants in mice.

1 reference

12 December 2020

On the importance and mechanisms of burst release in matrix-controlled drug delivery systems

1 reference

12 December 2020

Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.

1 reference

12 December 2020

Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development

1 reference

12 December 2020

Poly(lactic/glycolic acid) biodegradable drug-polymer matrix systems

1 reference

12 December 2020

Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients

1 reference

12 December 2020

Effects of risperidone on dopamine receptor subtypes in developing rat brain

1 reference

12 December 2020

Development of drug delivery systems for use in treatment of narcotic addiction.

1 reference

12 December 2020

Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.

1 reference

12 December 2020

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

1 reference

12 December 2020

Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats

1 reference

12 December 2020

Effect of drug type on the degradation rate of PLGA matrices

1 reference

12 December 2020

10.1007/S11095-010-0152-4

Identifiers

DOI

1 reference

13 November 2017

1 reference